EHA 2021 | Antibody deficiency and infectious complications in CLL
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses antibody deficiency and infectious complications in patients with chronic lymphocytic leukemia (CLL), in particular talking on immunoglobulin replacement therapy as a potential intervention for infections in patients with CLL, as well as commenting on COVID-19 vaccination. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Anthony Mato, MD, MSCE, has received research support from TG Therapeutics, Pharmacyclics, AbbVie, LOXO, Johnson & Johnson, Acerta/AZ, Regeneron, DTRM BioPharma, Sunesis, Loxo Oncology, Adaptive, Nurix, Genmab; and has participated in a advisory, consultancy of DSMB role for TG Therapeutics, Pharamacyclics, Adaptive, AbbVie, Johnson & Johnson, Acerta/AZ, DTRM BioPharma, Sunesis, Celgene, Versatem, Nurix, Genmab and LOXO.
